Shares of Johnson & Johnson (NYSE:JNJ - Get Free Report) traded down 0.1% during trading on Friday . The company traded as low as $153.71 and last traded at $154.19. 1,444,013 shares were traded during trading, a decline of 80% from the average session volume of 7,323,872 shares. The stock had previously closed at $154.28.
Analysts Set New Price Targets
A number of equities analysts have commented on the stock. HSBC raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating and lifted their target price for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, May 6th. Bank of America reduced their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 17th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 17th. Finally, StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, February 6th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $175.86.
Check Out Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Stock Performance
The company has a market cap of $372.27 billion, a PE ratio of 9.64, a P/E/G ratio of 2.52 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The stock's 50-day simple moving average is $152.40 and its 200 day simple moving average is $154.97.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business's revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.68 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.64 EPS for the current year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date of this dividend is Monday, May 20th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.19. Johnson & Johnson's dividend payout ratio (DPR) is currently 29.68%.
Hedge Funds Weigh In On Johnson & Johnson
A number of large investors have recently made changes to their positions in JNJ. Christopher J. Hasenberg Inc acquired a new stake in Johnson & Johnson in the 1st quarter valued at about $31,000. Keener Financial Planning LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $40,000. Tower View Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company's stock worth $40,000 after purchasing an additional 165 shares during the last quarter. WFA Asset Management Corp boosted its stake in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company's stock worth $40,000 after purchasing an additional 97 shares during the last quarter. Finally, Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $44,000. Hedge funds and other institutional investors own 69.55% of the company's stock.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
